

## Instructions for Authors 2018

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

### **Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.


5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2018** - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

# CANCER GENOMICS & PROTEOMICS

ISSN (online): 1790-6245



Published by the International Institute of Anticancer Research

Online ISSN: 1790-6245

## General Policy

- **CANCER GENOMICS & PROTEOMICS (CGP)** welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission.
- CGP is published bimonthly by the **International Institute of Anticancer Research (IIAR)** and is available online only and open access with **Stanford University HighWire Press**. The IIAR is a member of UICC. For more information please visit our website [www.cgp.iijournals.org](http://www.cgp.iijournals.org).
- **Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.  
**U.S. Branch:** Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.
- **E-mail:** [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org); IIAR WEBSITES: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iijournals.org](http://www.iijournals.org)

## ● Selection of Recent Articles

The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets. U.H. WEIDLE, S. DICKOPF, C. HINTERMAIR, G. KOLLMORGEN, F. BIRZELE, U. BRINKMANN (*Penzberg; Munich, Germany; Basel, Switzerland*)

Transcriptomic Profiling of MDA-MB-231 Cells Exposed to *Boswellia Serrata* and 3-O-Acetyl-B-Boswellic Acid; ER/UPR Mediated Programmed Cell Death. M.A. ELIZABETH, L.A. CHARLES, SOLIMAN F.A. KARAM (*Tallahassee, FL, USA*)

Screening for Multiple Autoantibodies in Plasma of Patients with Breast Cancer. L. BASSARO, S.J. RUSSELL, E. PASTWA, S.A. SOMIARI, R.I. SOMIARI (*Johnstown; Windber, PA, USA*)

DHPLC elution Patterns of VDR PCR Products Can Predict Prostate Cancer Susceptibility in African American Men. R.L. COPELAND, D. BEYENE, V. APPREY, M.R. DAREMPOURAN, T.J. NAAB, O.O. KASSIM, Y.M. KANAAN (*Washington, DC, USA*)

Characterization of Camptothecin-induced Genomic Changes in the Camptothecin-resistant T-ALL Derived Cell Line CPT-K5. E. KJELDSEN, C.J.F. NIELSEN, A. ROY, C. TESAURO, A.-K. JAKOBSEN, M. STOUGAARD, B.R. KNUDSEN (*Aarhus, Denmark*)

Regulation of  $\beta$ -Catenin Phosphorylation by PR55 $\beta$  in Adenoid Cystic Carcinoma. K. ISHIBASHI, K. ISHII, G. SUGIYAMA, Y. KAMATA, A. SUZUKI, W. KUMAMARU, Y. OHYAMA, H. NAKANO, T. KIYOSHIMA, T. SUMIDA, T. YAMADA, Y. MORI (*Fukuoka, Japan*)

Admixture Mapping Links RACGAP1 Regulation to Prostate Cancer in African Americans. B.D. WILSON, L.J. RICKS-SANTI, T.E. MASON, M. ABBAS, R.A. KITTLES, G.M. DUNSTON, Y.M. KANAAN (*Washington, DC; Hampton, VA; Duarte, CA, USA*)

Consistent Involvement of Chromosome 13 in Angiolipoma. I. PANAGOPOULOS, L. GORUNOVA, K. ANDERSEN, I. LOBMAIER, B. BJERKEHAGEN, S. HEIM (*Oslo, Norway*)

Analysis of K-Ras Interactions by Biotin Ligase Tagging. C. RITCHIE, A. MACK, L. HARPER, A. ALFADHLI, P.J.S. STORK, X. NAN, E. BARKLIS (*Portland, OR, USA*)

CYP3A4 Gene Is a Novel Biomarker for Predicting a Poor Prognosis in Hepatocellular Carcinoma. R. ASHIDA, Y. OKAMURA, K. OHSHIMA, Y. KAKUDA, K. UESAKA, T. SUGIURA, T. ITO, Y. YAMAMOTO, T. SUGINO, K. URAKAMI, M. KUSUHARA, K. YAMAGUCHI (*Shizuoka; Tokyo, Japan*)

Construction of Anti-HER2 Recombinants as Targeting Modules for a Drug-delivery System Against HER2-positive Cells. Q. TANG, M. ONITSUKA, A. TABATA, T. TOMOYASU, H. NAGAMUNE ( <i>Tokushima, Japan</i> ).....	4319
Possible Application of Ascites-infiltrating Gamma-delta T Cells for Adoptive Immunotherapy. Y. ABE, H. KOBAYASHI, Y. AKIZAWA, K. ISHITANI, K. HASHIMOTO, H. MATSUI ( <i>Tokyo, Japan</i> ).....	4327
Immunosuppression Induced by Perioperative Peritonitis Promotes Lung Metastasis. A. ARIMOTO, K. YAMASHITA, H. HASEGAWA, Y. SUGITA, E. FUKUOKA, T. TANAKA, S. SUZUKI, Y. KAKEJI ( <i>Kobe, Japan</i> ).....	4333
Dewaxed Brown Rice Feed Improves Fatty Liver in Obese and Diabetic Model Mice. H. INAGAWA, T. SAIKA, N. NISHIYAMA, T. NISIZAWA, C. KOHCHI, M. UENOBE, G.-I. SOMA ( <i>Kagawa; Niigata; Wakayama; Nagano, Japan</i> ) .....	4339
<i>Clinical Studies</i>	
Association of Serum HB-EGF Value and Response to Chemotherapy in Patients with Recurrent Ovarian Cancer. D. IZUCHI, S. FUKAGAWA, F. YOTSUMOTO, K. SHIGEKAWA, K. YOSHIKAWA, T. HIRAKAWA, C. KIYOSHIMA, N.S. OUK, D. URUSHIYAMA, T. KATSUDA, K. MIYATA, T. ITO, M. KURAKAZU, R. ARAKI, A. SANUI, D. MIYAHARA, M. MURATA, H. ITO, K. SHIROTA, M. KUROKI, S. YASUNAGA, S. MIYAMOTO ( <i>Fukuoka, Japan</i> ).....	4347
Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy. K. MAKITA, T. KAMIGAKI, S. OKADA, E. MATSUDA, H. IBE, E. OGUMA, K. NAITOH, R. TAKIMOTO, S. GOTO ( <i>Tokyo, Japan</i> ) .....	4353
Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel. S. IZUMOTO, M. MIYAUCHI, T. TASAKI, T. OKUDA, N. NAKAGAWA, N. NAKANO, A. KATO, M. FUJITA ( <i>Osaka-Sayama, Japan</i> ).....	4361
Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer. Y. YOSHIDA, R. SAKAMOTO, R. KAJITANI, T. MUNESHIKA, Y. MATSUMOTO, A. KOMONO, N. AISU, K. DAIBO, F. KIYOMI, S. HASEGAWA ( <i>Fukuoka, Japan</i> ) .....	4367
Improvement in Protracted Wound Healing by Topical Cream Containing Lipopolysaccharide Derived from <i>Pantoea agglomerans</i> . A. MORISHIMA, H. INAGAWA ( <i>Osaka; Kagawa, Japan</i> ).....	4375
Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients. H. MORI, M. KUBO, M. KAI, K. KURATA, M. YAMADA, M. NAKAMURA ( <i>Fukuoka, Japan</i> ).....	4381
Book Reviews .....	4387
Announcements .....	4389

**PROCEEDINGS OF THE 21st ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES**

*Review*

Application of iNKT Cell-targeted Active Immunotherapy in Cancer Treatment. K. YAMASHITA, A. ARIMOTO, M. NISHI, T. TANAKA, M. FUJITA, E. FUKUOKA, Y. SUGITA, A. NAKAGAWA, H. HASEGAWA, S. SUZUKI, Y. KAKEJI ( <i>Kobe; Osaka, Japan</i> ) .....	4233
---	------

*Experimental Studies*

Structure-associated Functional Control of TX-1877 Series by Glyco-conjugation. K. OHKURA, Y. KAWAGUCHI, Y. TATEMATSU, A. TABATA, Y. UTO, H. HORI ( <i>Suzuka; Choshi; Tokushima, Japan</i> ) .....	4241
---	------

Growth Suppression of Human Colorectal Cancer Cells with Mutated <i>KRAS</i> by 3-Deaza-cytarabine in 3D Floating Culture. H. LUO, K. NISHI, S. ISHIKURA, A. SWAIN, N. MORISHIGE, R. YAZAKI, T. OHSHIMA, S. SHIRASAWA, T. TSUNODA ( <i>Fukuoka, Japan</i> ).....	4247
--	------

Activated EphA2 Processing by MT1-MMP Is Involved in Malignant Transformation of Ovarian Tumours <i>In Vivo</i> . Y. TAKAHASHI, M. HAMASAKI, M. AOKI, K. KOGA, N. KOSHIKAWA, S. MIYAMOTO, K. NABESHIMA ( <i>Fukuoka, Japan; Kanagawa, Japan</i> ) .....	4257
---	------

Visualizing Energy Charge in Breast Carcinoma Tissues by MALDI Mass-spectrometry Imaging Profiles of Low-molecular-weight Metabolites. N. TORATA, M. KUBO, D. MIURA, K. OHUCHIDA, Y. MIZUUCHI, Y. FUJIMURA, E. HAYAKAWA, M. KAI, Y. ODA, K. MIZUMOTO, M. HASHIZUME, M. NAKAMURA ( <i>Fukuoka, Japan</i> ).....	4267
--	------

Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines. M. KUBO, M. UMEBAYASHI, K. KURATA, H. MORI, M. KAI, H. ONISHI, M. KATANO, M. NAKAMURA, T. MORISAKI ( <i>Fukuoka, Japan</i> ) .....	4273
---	------

Inhibition of Survivin by Adenovirus Vector Enhanced Paclitaxel induced Apoptosis in Breast Cancer Cells. T. TANAKA, H. UCHIDA ( <i>Fukuoka; Tokyo, Japan</i> ) .....	4281
---	------

Evaluation of a Hypertensive Rat Model Using Peripheral Blood Neutrophil Activity, Phagocytic Activity and Oxidized LDL Evaluation. R. ZHANG, H. INAGAWA, K. KAZUMURA, H. TSUCHIYA, T. MIWA, N. MORISHITA, S. UCHIBORI, J. HANASHIRO, T. MASAKI, H. KOBARA, G.-I. SOMA ( <i>Kagawa; Niigata; Hamamatsu, Japan</i> ).....	4289
--	------

Phagocytic Activation of Macrophages with Serum MAF Depends on Engulfment Efficiency and Not Migratory Activity. R. MASHIBA, M. ISHIKAWA, Y. SUMIYA, K. KAWAKATSU, N.K. TRAN, T. NISHIKATA ( <i>Kobe; Osaka, Japan</i> ).....	4295
---	------

Concentration-dependent Activation of Inflammatory/Anti-inflammatory Functions of Macrophages by Hydrolyzed Whey Protein. T. TASAKA, E. KUWADA, Y. IZUCHI, R. NISHIGAWA, H. YAMADA, H. UNUMA, K. TOKUNAGA, A. HAYAKAWA, A. GO, K. GO, Y. UTO ( <i>Tokyo; Tokushima, Japan</i> ) .....	4299
---	------

Global Liver Gene Expression Analysis on a Murine Hepatic Steatosis Model Treated with Mulberry ( <i>Morus alba</i> L.) Leaf Powder. H. UCHIYAMA, K.-I. KOMATSU, A. NAKATA, K. SATO, Y. MIHARA, A. TAKAGURI, T. NAGASHIMA, K. WAKAME ( <i>Tokyo; Hokkaido; Kanagawa, Japan</i> ).....	4305
---	------

Radiosensitizing Effect of 5-Aminolevulinic Acid and Protoporphyrin IX on Carbon-ion Beam Irradiation. T. KANEKO, M. TOMINAGA, R. KOUZAKI, A. HANYU, K. UESHIMA, H. YAMADA, M. SUGA, T. YAMASHITA, T. OKIMOTO, Y. UTO ( <i>Tosu; Tokushima; Tatsuno, Japan</i> ) .....	4313
--	------

Low-dose High-resolution <sup>18</sup> F-FDG-PET/CT Using Time-of-flight and Point-spread Function Reconstructions: A Role in the Detection of Breast Carcinoma Axillary Lymph Node Metastases. E. FERDOVÁ, J. BAXA, A. ŇARŠANSKÁ, O. HES, J. FÍNEK, O. TOPOLČAN, J. FERDA ( <i>Pilsen, Czech Republic</i> ) .....	4145
Tumor-related Perfusion Changes in White Matter Adjacent to Brain Tumors: Pharmacodynamic Analysis of Dynamic 3T Magnetic Resonance Imaging. R. TUPÝ, H. MÍRKA, J. MRAČEK, V. PŘIBÁŇ, O. HES, S. VOKURKA, J. FERDA ( <i>Pilsen, Czech Republic</i> ) .....	4149
Hybrid Imaging PET/CT with Application of <sup>18</sup> F-Fluorothymidine in Patients with Head and Neck Carcinoma Undergoing Radiotherapy. J. BAXA, J. FERDA, E. FERDOVA, R. VOJTISEK, O. TOPOLCAN, J. FINEK ( <i>Pilsen, Czech Republic</i> ) .....	4153
The Impact of Immune Interaction on the Metastatic Infiltration of Colorectal Carcinoma to Lymph Nodes. O. VYCITAL, M. DUBOVA, R. PALEK, P. HOSEK, J. BRANZOVSKY, V. TRESKA, O. DAUM, V. LISKA ( <i>Pilsen, Czech Republic</i> ) .....	4159
Antidiabetic Medication, Statins and the Risk and Prognosis of Non-endometrioid Endometrial Cancer in Women with Type 2 Diabetes. R. ARIMA, M. MARTTILA, A. HAUTAKOSKI, M. ARFFMAN, R. SUND, P. ILANNE-PARIKKA, J. KANGASKOKKO, E. URPILAINEN, E. LÄÄRÄ, M. HINKULA, U. PUISTOLA ( <i>Oulu; Helsinki; Kuopio; Tampere, Finland</i> ) .....	4169
Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel. H. MIYAKE, Y. MATSUSHITA, H. WATANABE, K. TAMURA, T. SUZUKI, D. MOTOYAMA, T. ITO, T. SUGIYAMA, A. OTSUKA ( <i>Hamamatsu, Japan</i> ) .....	4179
Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis. M. DIMOU, T. ILIAKIS, D. MALTEZAS, A. BITSANI, S. KALYVA, A. KOUDOUNA, S. KOTSANTI, P. PETSAS, P. PAPAIOANNOU, M.-C. KYRTSONIS, P. PANAYIOTIDIS ( <i>Athens, Greece</i> ) .....	4187
Neoadjuvant Radiotherapy with Capecitabine Plus Bevacizumab for Locally Advanced Lower Rectal Cancer: Results of a Single-institute Phase II Study. K. MAEDA, M. SHIBUTANI, H. OTANI, T. FUKUOKA, Y. ISEKI, S. MATSUTANI, H. NAGAHARA, T. INOUE, A. TACHIMORI, T. NISHII, Y. MIKI, M. HOSONO, M. OHIRA ( <i>Osaka, Japan</i> ) .....	4193
A Tool to Predict the Probability of Intracerebral Recurrence or New Cerebral Metastases After Whole-brain Irradiation in Patients with Head-and-Neck Cancer. C. STAACKMANN, S. JANSSEN, S.E. SCHILD, D. RADES ( <i>Lübeck; Hannover, Germany; Scottsdale, AZ, USA</i> ) .....	4199
Unusual Papillary Squamous Cell Carcinoma of the Tip of Tongue Presenting in a Patient Status Post Heart Transplant. F. ALOTAIBY, F. SONG, B.J. BOYCE, D. CAO, Y. ZHAO, J. LAI ( <i>Gainesville, FL; St. Louis, MO, USA; Changsha; Zhengzhou, PR China</i> ) .....	4203
Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer. K. TAMARI, R.-J. OH, N. MASAI, H. SHIOMI, K. OTANI, O. SUZUKI, K. OGAWA ( <i>Osaka, Japan</i> ) .....	4207
Skin Reaction to Cetuximab as a Criterion for Treatment Selection in Head and Neck Cancer. P. STROJAN, B. ZAKOTNIK, B. ŽUMER, K. KARNER, M. DREMELJ, B. JANČAR, S. JEREB, C. GRAŠIČ-KUHAR ( <i>Ljubljana, Slovenia</i> ) .....	4213
Prevalence of High-risk HPV in Postmenopausal Women with Benign Cervical Cytology – A Population-based Cohort Study. K.C. ASCIUTTO, O. FORSLUND, C. BORGFELDT ( <i>Lund, Sweden</i> ) .....	4221

Prediction of Non-sentinel Lymph Node Metastases After Positive Sentinel Lymph Nodes Using Nomograms. I. GRUBER, M. HENZEL, B. SCHÖNFISCH, A. STÄBLER, F.-A. TARAN, M. HAHN, C. RÖHM, G. HELMS, E. OBERLECHNER, B. WIESINGER, K. NIKOLAOU, C. LA FOUGÈRE, D. WALLWIENER, A. HARTKOPF, N. KRAWCZYK, T. FEHM, S. BRUCKER ( <i>Tübingen; Filderstadt-Bonlanden; Düsseldorf, Germany</i> ) .....	4047
Expression and Prognostic Impact of VEGF, CD31 and $\alpha$ SMA in Resected Primary Lung Cancers. K. USUDA, S. IWAI, A. FUNASAKI, A. SEKIMURA, N. MOTONO, Y. UEDA, M. SHIMAZAKI, H. URAMOTO ( <i>Ishikawa, Japan</i> ) .....	4057
Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors. S. MIWA, T. MOCHIZUKI, N. YAMAMOTO, T. SHIRAI, K. HAYASHI, A. TAKEUCHI, H. INATANI, K. IGARASHI, T. HIGUCHI, K. ABE, Y. TANIGUCHI, H. AIBA, H. IKEDA, H. TSUCHIYA ( <i>Kanazawa, Japan</i> ) .....	4065
Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer. K. SAKAGUCHI, K. NAKATSUKASA, H. KOYAMA, M. KATO, A. SAKUYAMA, T. MATSUDA, N. TSUNODA, I. FUJIWARA, M. YAMAGUCHI, H. TANAKA, K. ONISHI, M. ONISHI, Y. YOSHINO, T. KIKUCHI, T. TAGUCHI ( <i>Kyoto; Nara; Shiga; Aichi; Osaka; Ishikawa; Kobe, Japan</i> ) .....	4073
Unilateral Creeping Destruction of Deformed Mandibular Ramus and Angle Associated with Extensive Facial Plexiform Neurofibroma in Neurofibromatosis Type 1: A Case Report with Analysis of the Literature for Diagnosing Osteolytic Events of the Mandible in Tumor-suppressor Gene Syndrome. R.E. FRIEDRICH, H.A. SCHEUER ( <i>Hamburg, Germany</i> ).....	4083
Predicting Poorly Differentiated Hepatocellular Carcinoma that Meets the Milan Criteria. Y. KOGA, T. BEPPU, T. MIYATA, Y. KITANO, A. TSUJI, S. NAKAGAWA, K. ARIMA, K. KURAMOTO, H. OKABE, K. IMAI, H. HAYASHI, H. NITTA, Y.-I. YAMASHITA, A. CHIKAMOTO, T. ISHIKO, H. BABA ( <i>Kumamoto, Japan</i> ) .....	4093
EpCAM as a Predictive Marker of Tumor Recurrence and Survival in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma. C.-K. NOH, H.J. WANG, C.M. KIM, J. KIM, S.Y. YOON, G.H. LEE, H.J. CHO, M.J. YANG, S.S. KIM, J.C. HWANG, S.W. CHO, J. ROH, Y.B. KIM, S.J. KIM, B.W. KIM, J.Y. CHEONG ( <i>Suwon; Daejeon, Republic of Korea</i> ) .....	4101
DNA from Human Polyomaviruses, MWPvV, HPyV6, HPyV7, HPyV9 and HPyV12 in Cutaneous T-cell Lymphomas. M. BERGALLO, V. DAPRÀ, P. FAVA, R. PONTI, C. CALVI, P. MONTANARI, M. NOVELLI, P. QUAGLINO, I. GALLIANO, M.T. FIERRO ( <i>Turin, Italy</i> ) .....	4111
Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer. T. MURAKAMI, H. OBATA, N. AKITAKE, M. SHIOTA, A. TAKEUCHI, E. KASHIWAGI, J. INOKUCHI, K. TATSUGAMI, M. ETO ( <i>Fukuoka, Japan</i> ) .....	4115
Pathological High-risk Renal Cell Carcinoma: Trends in Clinical Characteristics Over 25 Years. E. DI TRAPANI, P. DELL'OGGIO, A. LARCHER, A. NINI, F. MUTTIN, F. CIANFLONE, F. DEHÒ, R. MATLOOB, D. DI TRAPANI, M. FRESCHI, A. SALONIA, A. BRIGANTI, F. MONTORSI, R. BERTINI, U. CAPITANIO ( <i>Milan, Italy</i> ).....	4123
Single-source Dual-energy CT as a Part of $^{18}$ F-FDG PET/CT: Direct Comparison of Iodine-related and Metabolic Parameters in Non-small Cell Lung Cancer. J. BAXA, T. MATOUSKOVA, J. LUDVIK, M. SEDLMAIR, T. FLOHR, B. SCHMIDT, J. BEJCEK, M. PESEK, J. FERDA ( <i>Pilsen, Czech Republic; Forchheim, Germany</i> ) .....	4131
$^{18}$ F-Fluorocholine PET/MRI in Restaging of Prostatic Carcinoma in Relation to PSA Level and Detection of Active Disease. J. FERDA, E. FERDOVÁ, J. BAXA, J. FÍNEK, O. TOPOLČAN ( <i>Pilsen, Czech Republic</i> ).....	4139



Melatonin Promotes Apoptosis of Colorectal Cancer Cells <i>via</i> Superoxide-mediated ER Stress by Inhibiting Cellular Prion Protein Expression. C.W. YUN, S. KIM, J.H. LEE, S.H. LEE (Seoul; Cheonan, Republic of Korea; Birmingham, AL, USA) .....	3951
Genetic Mutations in a Patient with Chronic Myeloid Leukemia Showing Blast Crisis 10 Years After Presentation. L.-M. SKLARZ, C. WITTKKE, S. KROHN, C. GROSSE-THIE, C. JUNGHANSS, H.M. ESCOBAR, H. GLAESER (Rostock, Germany) .....	3961
Combination Effects of Hispidin and Gemcitabine <i>via</i> Inhibition of Stemness in Pancreatic Cancer Stem Cells. N. CHANDIMALI, D.L. HUYNH, W.Y. JIN, T. KWON (Jeju, Republic of Korea).....	3967
Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies. E. DESTANOVIC, J. BOOS, C. LANVERS-KAMINSKY (Muenster, Germany) .....	3977
Alterations of p53 and Rb Pathways Are Associated with High Proliferation in Bladder Urothelial Carcinomas. A.C. GOUSSIA, A. PAPOUDOU-BAI, A. CHARCHANTI, P. KITSOULIS, P. KANAVAROS, J. KALEF-EZRA, D. STEFANO, N.J. AGNANTIS (Ioannina, Greece) .....	3985
Bisdemethoxycurcumin Suppresses Migration and Invasion of Human Cervical Cancer HeLa Cells <i>via</i> Inhibition of NF- $\kappa$ B, MMP-2 and -9 Pathways. C.-L. LIAO, Y.L. CHU, H.-Y. LIN, C.-Y. CHEN, M.-J. HSU, K.-C. LIU, K.-C. LAI, A.-C. HUANG, J.-G. CHUNG (Taichung; Pingtung; Tainan; Beigang; Yilan, Taiwan, ROC).....	3989
<i>In Vitro</i> Evaluation of the Multidrug Resistance Reversing Activity of Novel Imidazo[4,5-b]pyridine Derivatives. S. BOURICHI, H. MISBAHI, Y.K. RODI, F.O. CHAHDI, E.M. ESSASSI, S. SZABÓ, B. SZALONTAI, M. GAJDÁCS, J. MOLNÁR, G. SPENGLER (Fez; Rabat, Morocco; Szeged, Hungary).....	3999
Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in the Serum of Patients with Non-alcoholic Fatty Liver Disease. W. JELSKI, B. WOLSZCZAK-BIEDRZYCKA, E. ZASIMOWICZ-MAJEWSKA, K. ORYWAL, T.W. LAPINSKI, M. SZMITKOWSKI (Bialystok; Olsztyn, Poland).....	4005
Chloroquine Used in Combination with Chemotherapy Synergistically Suppresses Growth and Angiogenesis <i>In Vitro</i> and <i>In Vivo</i> . E. GUREL-GUREVIN, H.T. KIYAN, O.B.B. ESENER, S. AYDINLIK, A. UVEZ, E. ULUKAYA, K. DIMAS, E.I. ARMUTAK (Istanbul; Eskisehir; Bursa, Turkey; Larissa, Greece) .....	4011
Associations Between <i>MTHFR</i> Polymorphisms and the Risk of Potentially Malignant Oral Disorders. T. SENGHORE, Y.-F. LI, F.-C. SUNG, M.-H. TSAI, C.-H. HUA, C.-S. LIU, M.-F. HUNG, C.-C. YEH (Taipei; Taichung, Taiwan, ROC) .....	4021
<i>Clinical Studies</i>	
Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma. T.M. SCHMIDT, L. LIU, I.E. ABRAHAM, A.B. UY, A.Z. DUDEK (Chicago, IL; St. Paul, MN, USA) .....	4027
Neoadjuvant <i>Nab</i> -paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX. S.L. PETERSON, M. HUSNAIN, T. POLLACK, A. PIMENTEL, A. LOAIZA-BONILLA, C. WESTENDORF-OVERLEY, K. RATERMANN, L. ANTHONY, P. DESIMONE, G. GOEL, M. KUDRIMOTI, S. DINEEN, C.-W.D. TZENG, P.J. HOSEIN (Louisville; Lexington, KY; Miami; Tampa, FL; Philadelphia; Pittsburgh, PA; Houston, TX, USA).....	4035
Pancreaticoduodenectomy for the Management of Pancreatic or Duodenal Metastases from Primary Sarcoma. J.R. HUDDY, M.H. SODERGREN, J. DEGUARA, K. THWAY, R.L. JONES, S.S. MUDAN (London, UK).....	4041

Hydrogen Sulfide Is Increased in Oral Squamous Cell Carcinoma Compared to Adjacent Benign Oral Mucosae. A.T. MERAM, J. CHEN, S. PATEL, D.D. KIM, B. SHIRLEY, P. COVELLO, D. COPPOLA, E.X. WEI, G. GHALI, C.G. KEVIL, R.E. SHACKELFORD ( <i>Shreveport, LA; Tampa, FL, USA</i> ).....	3843
Analysis of Anticancer Activity and Chemical Sensitization Effects of <i>Dendropanax morbifera</i> and <i>Commersonia bartramia</i> Extracts. S. KIM, S.G. PARK, Y.J. SONG, J.K. PARK, C.H. CHOI, S. LEE, R.M. HOFFMAN ( <i>Seoul; Seongnam; Gwangju, Republic of Korea; San Diego, CA, USA</i> ) .....	3853
Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms. F. BRIEST, Y. WANG, R. ARSENIC, S. ELEZKURTAJ, E. BERG, S. GRESHAKE, A.C. LOCK, D. HÖRSCH, C.N. ARNOLD, M. HUMMEL, B. SIEGMUND, P. GRABOWSKI ( <i>Berlin; Bad Berka; Friedrichshafen, Germany</i> ).....	3863
Polymorphisms in <i> Twist1</i> and <i>ZEB1</i> Are Associated with Prognosis of Gastric Cancer Patients. S. ROMERO, M. MUSLEH, M. BUSTAMANTE, J. STAMBUK, R. PISANO, E. LANZARINI, H. CHIONG, J. ROJAS, V.G. CASTRO, L. JARA, Z. BERGER, P. GONZALEZ-HORMAZABAL ( <i>Santiago, Chile</i> ) .....	3871
MART-10, a $1\alpha,25(\text{OH})_2\text{D}_3$ Analog, Potently Represses Metastasis of ER+ Breast Cancer Cells with VEGF-A Overexpression. K.-C. CHIANG, C.-N. YEH, T.-S. YEH, H.-H. JUANG, L.-W. CHEN, S.-F. KUO, M.-H. CHEN, T.C. CHEN, M. TAKANO, A. KITAKA, J.-H.S. PANG ( <i>Keelung; Taoyuan; Taipei, Taiwan, R.O.C.; Boston, MA, USA; Sagamihara, Japan</i> ).....	3879
Comparison of Microvessel Density Using Nestin and CD34 in Colorectal Cancer. M. CHABOWSKI, A. NOWAK, J. GRZEGRZOLKA, A. PIOTROWSKA, D. JANCZAK, P. DZIEGIEL ( <i>Wroclaw, Poland</i> ) .....	3889
Quantitative Structure–Cytotoxicity Relationship of 2-( <i>N</i> -cyclicamino)chromone Derivatives. H. SHI, J. NAGAI, T. SAKATSUME, K. BANDOW, N. OKUDAIRA, H. SAKAGAMI, M. TOMOMURA, A. TOMOMURA, Y. UESAWA, K. TAKAO, Y. SUGITA ( <i>Shanghai, PR China; Saitama; Tokyo, Japan</i> ) .....	3897
The Association of Matrix Metalloproteinase-1 Promoter Polymorphisms with Prostate Cancer in Taiwanese Patients. C.-H. LIAO, H.-C. WU, P.-S. HU, S.-W. HSU, T.-C. SHEN, T.-C. HSIA, W.-S. CHANG, C.-W. TSAI, D.-T. BAU ( <i>Taichung; Taipei; Changhua, Taiwan, ROC</i> ).....	3907
CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer. S. SCHMID, A. CSANADI, N. KOZHUHAROV, M. TCHUDJIN, C. KAYSER, J. RAWLUK, B. PASSLICK, M. WERNER, A. PRASSE, G. KAYSER ( <i>Freiburg; Hannover, Germany; Basel, Switzerland</i> ) .....	3913
The Shielding Ability of Novel Tungsten Rubber Against the Electron Beam for Clinical Use in Radiation Therapy. K. KIJIMA, H. MONZEN, K. MATSUMOTO, M. TAMURA, Y. NISHIMURA ( <i>Osaka; Shiga, Japan</i> ) .....	3919
CD117 Expression in Squamous Cell Carcinoma of the Oesophagus. L.F. MOREIRA, M.M. MAINO, H.I. GARBIN, G.R. DA NATIVIDADE, B.S. VOLKWEIS, J.U. KULCZYNSKI ( <i>Porto Alegre, Brazil</i> ) .....	3929
The Potential of Exosomes Derived from Chronic Myelogenous Leukaemia Cells as a Biomarker. K.-W. KANG, J.-H. JUNG, W. HUR, J. PARK, H. SHIN, B. CHOI, H. JEONG, D.S. KIM, E.S. YU, S.R. LEE, H.J. SUNG, S.J. KIM, C.W. CHOI, H.K. KIM, S. HONG, J.-H. PARK, Y. CHOI, Y. PARK, B.S. KIM ( <i>Seoul; Daejeon, Republic of Korea</i> ) .....	3935
Gelsolin-like Actin-capping Protein (CapG) Overexpression in the Cytoplasm of Human Hepatocellular Carcinoma, Associated with Cellular Invasion, Migration and Tumor Prognosis. T.-J. TSAI, W.-Y. CHAO, C.-C. CHEN, Y.-J. CHEN, C.-Y. LIN, Y.-R. LEE ( <i>Chiayi; Tainan, Taiwan, ROC</i> ).....	3943